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2.  Binding 3.  Washing
Discovery of human scFvs by phage display
Based on a combined toxicovenomics and phage display selection
approach5, 431 human scFv binders were isolated from a phage
display library against the medically relevant neurotoxins and
dendrotoxins of D. polylepis.
Conversion of unique scFv binders to IgG
Following expression of 147 scFvs with unique VH CDR3 regions in
E. coli and evaluation of binding strength, the 24 most promising
scFvs were selected and converted to IgG format. Of these, 20
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Currently, the binding affinities and the neutralization potential of
these 20 toxin-­‐‑targeting IgGs is being investigated with the aim of
being able to design a cost-­‐‑effective recombinant oligoclonal
mixture of IgGs6 that can effectively neutralize the lethal effects of
the synergistically-­‐‑acting venom of D. polylepis7.
Short  neurotoxin Long  neurotoxin Dendrotoxin
Snakebite: a neglected tropical disease
Snakebite envenoming is a major cause of death and morbidity in
tropical parts of the world. Current therapies are based on animal-­‐‑
derived antisera that are associated with a high degree of
immunogenicity, high cost, and batch-­‐‑to-­‐‑batch variation1,2. Here, we
report the results of our ongoing efforts of developing the world’s
first fully recombinant antivenom based on human IgGs targeting
the key toxins3 from the notorious black mamba (Dendroaspis
polylepis)4.
Oligoclonal  expression  of  human  IgGs
